10-Q: Rani Therapeutics Faces Going Concern Doubt Amid Nasdaq Delisting Threat

Rani Therapeutics Holdings, Inc. reported continued losses and substantial doubt about its ability to continue as a going concern, alongside receiving notices of non-compliance with Nasdaq's minimum bid price and market value requirements.

Summary

• Reported a net loss of $23.962 million for the six months ended June 30, 2025, compared to $28.140 million for the same period in 2024.
• Experienced negative cash flows from operations of $13.9 million for the six months ended June 30, 2025.
• Cash, cash equivalents, and marketable securities totaled $10.2 million as of June 30, 2025.
• Management has concluded there is substantial doubt about the company's ability to continue as a going concern for a period of one year after the financial statements' issuance date.
• Received notices from Nasdaq for non-compliance with both the minimum bid price requirement ($1.00 per share) and the minimum market value of listed securities requirement ($50 million).
• Preclinical data for RT-114 (bispecific GLP-1/GLP-2 receptor agonist) demonstrated bioequivalence to subcutaneously administered PG-102, with 111% relative bioavailability and comparable weight loss.
• Preclinical data for RT-116 (oral semaglutide via RaniPill HC) showed comparable bioavailability, pharmacokinetics, and weight loss to subcutaneous semaglutide.
• Entered into a securities purchase agreement in July 2025 for $3.0 million gross proceeds from an institutional investor.
• Existing capital resources are insufficient to initiate any pivotal clinical trials.

Sentiment

Score: 2

Explanation: The company faces severe financial distress, including substantial doubt about its ability to continue as a going concern and Nasdaq delisting threats. While preclinical data shows promise, the immediate financial instability and urgent need for significant capital overshadow these scientific advancements, indicating a very high-risk investment.

Positives

• Net loss decreased to $23.962 million for the six months ended June 30, 2025, from $28.140 million in the prior year period.
• Research and development expenses decreased by $1.6 million (11.9%) for the six months ended June 30, 2025, compared to the prior year period.
• General and administrative expenses decreased by $2.2 million (17.4%) for the six months ended June 30, 2025, compared to the prior year period.
• Preclinical data for RT-114 demonstrated bioequivalence to subcutaneously administered PG-102, with 111% relative bioavailability and comparable weight loss.
• Preclinical data for RT-116 (oral semaglutide via RaniPill HC) showed comparable bioavailability, pharmacokinetics, and weight loss to subcutaneous semaglutide.
• Successful oral delivery of two undisclosed Chugai Pharmaceutical Co., Ltd. molecules via RaniPill HC, demonstrating comparable bioavailability to subcutaneous delivery.

Negatives

• Incurred recurring losses since inception, with a net loss of $23.962 million for the six months ended June 30, 2025.
• Accumulated deficit of $116.9 million as of June 30, 2025.
• Negative cash flows from operations of $13.9 million for the six months ended June 30, 2025.
• Substantial doubt exists about the company's ability to continue as a going concern for one year after the financial statements' issuance date.
• Existing capital resources ($10.2 million as of June 30, 2025, plus $3.0 million from July 2025 offering) are insufficient to initiate any pivotal clinical trials.
• Received Nasdaq notices for non-compliance with the minimum bid price requirement ($1.00 per share) and the minimum market value of listed securities requirement ($50 million).
• Anticipates existing cash and cash equivalents will not be sufficient to meet operating and liquidity needs beyond late September 2025 without additional sources of liquidity.
• Repayment of debt of $7.5 million for the six months ended June 30, 2025.

Risks

• There is substantial doubt regarding the company's ability to continue as a going concern, which could lead to a total loss of investment for common stock holders.
• Inability to raise additional funding on acceptable terms, or at all, could force the company to delay, limit, reduce, or terminate product development programs, commercialization efforts, or operations, or even file for bankruptcy.
• Failure to meet Nasdaq's continued listing requirements (minimum bid price of $1.00 and minimum market value of listed securities of $50 million) could result in delisting, negatively impacting stock price and ability to raise additional capital.
• International trade policies, including tariffs, sanctions, and trade barriers, may adversely affect business, financial condition, results of operations, and prospects, particularly due to reliance on third-party suppliers in various countries (e.g., Korea, China for drug substances).
• The 'baby shelf rules' (less than $75 million public float) limit the amount of securities registrable on Form S-3 to one-third of public float over a 12-month period, potentially making future capital raises more difficult, costly, and time-consuming.
• The Lender has a security interest in substantially all of the company's assets, including intellectual property, which may prevent or limit the ability to incur additional indebtedness.

Future Outlook

The company expects to continue generating operating losses and negative operating cash flows for the foreseeable future. It will need to raise substantial additional funds to complete the development of the RaniPill platform, advance product candidates through clinical development and regulatory approval, expand manufacturing capabilities, further develop the RaniPill HC device, and commercialize any product candidates. Existing capital resources are anticipated to be insufficient to meet operating and liquidity needs beyond late September 2025. Clinical testing of the RaniPill HC is intended to be initiated in the second half of 2025.

Management Comments

• "Based on our available cash resources and current operating plan, there is substantial doubt regarding our ability to continue as a going concern for a period of one year after the date that our financial statements for the six months ended June 30, 2025 are issued."
• "Our existing capital resources, including the net proceeds from the Offering, will not be sufficient to enable us to initiate any pivotal clinical trials."

Industry Context

Rani Therapeutics operates in the highly competitive and capital-intensive biotherapeutics industry, specifically focusing on oral drug delivery to replace injectable therapies. Its RaniPill platform, including RaniPill GO and RaniPill HC, aims to deliver biologics and drugs orally. The company's preclinical work on RT-114 (a bispecific GLP-1/GLP-2 receptor agonist) and RT-116 (oral semaglutide) targets the rapidly growing obesity and diabetes markets, currently dominated by injectable treatments. While the preclinical data showing comparable bioavailability to subcutaneous delivery is a significant scientific advancement, the company's severe financial instability and urgent need for capital pose substantial challenges to its ability to capitalize on these innovations and compete effectively.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct assessment against broader industry benchmarks.
• Preclinical results for RT-114 and RT-116 are presented as demonstrating comparable bioavailability, pharmacokinetics, and weight loss to subcutaneous administration, which serves as a key internal benchmark for the RaniPill technology's efficacy.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any litigation or legal proceedings that are likely to have a material adverse effect on its business.
• The company accounts for estimated losses with respect to legal proceedings and claims when such losses are probable and estimable.

Related Party Transactions

• InCube Labs, LLC (ICL), wholly-owned by the company's founder and Chairman and his family, provides and receives personnel and occupancy services under service agreements (Rani LLC-ICL Service Agreement and RMS-ICL Service Agreement).
• Rani LLC pays for the use of its San Jose, California facility through the RMS-ICL Service Agreement.
• ICL charged the company $0.167 million for services and rent (net) for the three months ended June 30, 2025, and $0.339 million for the six months ended June 30, 2025.
• The company has a fully paid, exclusive license under certain patents from ICL related to optional features of the RaniPill device.
• The company has the right to acquire four specified United States patent families from ICL for a one-time payment of $0.3 million each, up to $1.0 million in aggregate, starting from the fifth anniversary of the Amended and Restated Exclusive License Agreement.
• The company granted ICL a non-exclusive, fully-paid license under specified patents that were assigned from ICL to the company, with restrictions on licensing to third parties in specific fields.
• Certain parties to the Tax Receivable Agreement (TRA), including ICL and its affiliates, are related parties. The TRA provides for payment of 85% of tax benefits from exchanges of Paired Interests, but no liability has been recorded as it's not probable the company will realize such benefits.
• ICL and its affiliates, as Continuing LLC Owners, can exchange Paired Interests for Class A common stock or cash.

Stakeholder Impact

• Shareholders face a high risk of total loss of investment due to substantial doubt about the company's ability to continue as a going concern and potential Nasdaq delisting.
• Employees may face workforce reductions or job insecurity if the company is unable to secure additional funding or is forced to restructure or liquidate.
• Creditors, particularly the Lender, have a security interest in substantially all of the company's assets, which may impact their recovery in a liquidation scenario.
• Customers and partners (e.g., ProGen, Chugai) may experience disruptions or termination of collaborations if the company's financial instability prevents further development or commercialization of product candidates.

Next Steps

• Raise substantial additional funds to complete RaniPill platform development, clinical development of product candidates, seek regulatory approval, expand manufacturing, further develop RaniPill HC, and commercialize products.
• Monitor Class A common stock bid price to regain compliance with Nasdaq's minimum bid price requirement by December 17, 2025.
• Achieve and maintain a market value of listed securities of at least $50 million to regain compliance with Nasdaq's MVLS requirement by October 28, 2025.
• Initiate clinical testing of the RaniPill HC in the second half of 2025.
• Continue to develop the RaniPill capsule technology and advance product candidates.
• Potentially file a voluntary petition for relief under the United States Bankruptcy Code if unable to obtain additional funding or meet obligations.

Key Dates

Recommendation

The company is facing severe financial distress, explicitly stating 'substantial doubt regarding our ability to continue as a going concern' and that existing capital is insufficient beyond late September 2025. It also faces imminent delisting from Nasdaq due to non-compliance with minimum bid price and market value requirements. While preclinical data for its RaniPill technology is promising, the company's immediate liquidity crisis and the high probability of bankruptcy or significant dilution make it an extremely high-risk investment. The recent capital raises are insufficient to address the long-term funding needs, especially for pivotal clinical trials. Investors face a high risk of total loss.

Keywords

Rani Therapeutics, RaniPill, oral drug delivery, biotherapeutics, GLP-1, GLP-2, semaglutide, obesity, diabetes, preclinical data, clinical trials, Nasdaq listing, going concern, capital raise, RT-114, RT-116, drug development, pharmaceutical, biotechnology